Galapagos increases share capital through warrant exercises
December 04 2015 - 4:04PM
Galapagos NV (Euronext & NASDAQ: GLPG) announced a share
capital increase arising from warrant exercises.
Galapagos issued 63,500 new ordinary shares on
4 December 2015, for a total capital increase (including
issuance premium) of €590,800.00.
Pursuant to the rules of the warrant exercise
program of Galapagos' Executive Committee adopted in 2013,
Executive Committee members automatically are committed to exercise
a minimum number of warrants, subject to certain conditions.
Accordingly, CEO Onno van de Stolpe exercised 10,000 warrants and
has consequently increased his holding to a total of 538,289
shares; two other Executive Committee members exercised an
aggregate amount of 5,000 warrants.
In accordance with Belgian transparency
legislation1, Galapagos notes that its total share capital
currently amounts to € 211,388,857.22; the total number of
securities conferring voting rights is 39,076,342, which is also
the total number of voting rights (the "denominator"), and all
securities conferring voting rights and all voting rights are of
the same category. The total number of rights (warrants) to
subscribe to not yet issued securities conferring voting rights is
2,805,692, which equals the total number of voting rights that may
result from the exercise of these warrants. Galapagos does
not have any convertible bonds or shares without voting rights
outstanding. About Galapagos Galapagos (Euronext &
NASDAQ: GLPG) is a clinical-stage biotechnology company specialized
in the discovery and development of small molecule medicines with
novel modes of action. Our pipeline comprises three Phase 2,
three Phase 1 and five pre-clinical, and 20 discovery studies in
cystic fibrosis, inflammation, fibrosis, osteoarthritis and other
indications. We are focused on the development and
commercialization of novel medicines that will improve people's
lives. The Galapagos group, including fee-for-service
subsidiary Fidelta has approximately 400 employees, operating
from its Mechelen, Belgium headquarters and facilities in The
Netherlands, France, and Croatia. More information at
www.glpg.com.
Contacts
Investors: Media:
Elizabeth
Goodwin Evelyn
Fox VP IR & Corporate
Communications Director
Communications Tel: +1 781 460
1784 Tel:
+31 6 53 591 999
ir@glpg.com communications@glpg.com
Forward-looking statements This release may contain
forward-looking statements, all of which involve certain risks and
uncertainties. These statements are often, but not always,
made through the use of words or phrases such as "anticipates,"
"believes," "continues," "could," "estimates," "expects,"
"intends," "may," "plans," "seeks," "stands to," "we believe,"
"will," "we intend," as well as similar expressions. Such
forward-looking statements involve known and unknown risks,
uncertainties and other factors which might cause the actual
results, financial condition and liquidity, performance or
achievements of Galapagos, or industry results, to be materially
different from any historic or future results, financial conditions
and liquidity, performance or achievements expressed or implied by
such forward-looking statements. In addition, even if
Galapagos' results, performance, financial condition and liquidity,
and the development of the industry in which it operates are
consistent with such forward-looking statements, they may not be
predictive of results or developments in future periods.
Among the factors that may result in differences are the inherent
uncertainties associated with competitive developments, clinical
trial and product development activities and regulatory approval
requirements (including that data from Galapagos' ongoing clinical
research programs may not support registration or further
development of its product candidates due to safety, efficacy or
other reasons), Galapagos' reliance on collaborations with third
parties, and estimating the commercial potential of Galapagos'
product candidates. A further list and description of these
risks, uncertainties and other risks can be found in Galapagos'
Securities and Exchange Commission (SEC) filings and reports,
including in Galapagos' prospectus filed with the SEC on 14 May
2015 and future filings and reports filed by Galapagos with the
SEC. Given these uncertainties, the reader is advised not to
place any undue reliance on such forward-looking statements.
These forward-looking statements speak only as of the date of
publication of this document. Galapagos expressly disclaims
any obligation to update any such forward-looking statements in
this document to reflect any change in its expectations with regard
thereto or any change in events, conditions or circumstances on
which any such statement is based or that may affect the likelihood
that actual results will differ from those set forth in the
forward-looking statements, unless specifically required by law or
regulation.
1 Belgian Act of 2 May 2007 on the disclosure of
major shareholdings in issuers whose shares are admitted to trading
on a regulated market
GLPG increases share capital through warrant exercises
http://hugin.info/133350/R/1971576/720944.pdf
HUG#1971576
Galapagos (EU:GLPG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Galapagos (EU:GLPG)
Historical Stock Chart
From Jul 2023 to Jul 2024